Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: A go-DARTS study

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 1, 2010, Pages 52-56

  Zhou, K ^a   Donnelly, L ^a   Burch, L ^a   Tavendale, R ^a   Doney, A S F ^a   Leese, G ^a   Hattersley, A T ^b   McCarthy, M I ^c,d,e   Morris, A D ^a   Lang, C C ^f   Palmer, C N A ^a   Pearson, E R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; UNITED KINGDOM; WILD TYPE;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; DATABASES, GENETIC; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC VARIATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCOTLAND; SULFONYLUREA COMPOUNDS;

EID: 72849111539     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.176     Document Type: Article

References (9)

1. Hermann, L.S., Scherstén, B. & Melander, A. antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet. Med. 11, 953-960 (1994).
2. Feng, Y. et al. Ser1369ala variant in sulfonylurea receptor gene aBCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 31, 1939-1944 (2008).
3. Pearson, E.R. et al. Variation in TCF7L2 infuences therapeutic response to sulfonylureas: a GoDaRTs study. Diabetes 56, 2178-2182 (2007).
4. Kirchheiner, J. et al. Impact of CyP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 71, 286-296 (2002). (Pubitemid 34311458)
5. Kirchheiner, J. et al. Impact of CyP2C9 and CyP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12, 101-109 (2002). (Pubitemid 34298914)
6. Becker, M.L., Visser, L.E., Trienekens, P.H., Hofman, A., Van Schaik, R.H. & Stricker, B.H. Cytochrome P450 2C9 &z.ast;2 and &z.ast;3 polymorphisms and the dose and efect of sulfonylurea in type II diabetes mellitus. Clin. Pharmacol. Ther. 83, 288-292 (2008).
7. Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B. & Brockmöller, J. Efect of genetic polymorphisms in cytochrome p450 (CyP) 2C9 and CyP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet. 44, 1209-1225 (2005).
8. Holstein, A. et al. association between CyP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 60, 103-106 (2005).
9. Morris, A.D., Boyle, D.I., McMahon, A.D., Greene, S.A., MacDonald, T.M. & Newton, R.W. adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DaRTS/MEMO Collaboration. Diabetes audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 350, 1505-1510 (1997).